Literature DB >> 21378564

Inflammation and cardiac outcome.

Philipp J Hohensinner1, Alexander Niessner, Kurt Huber, Cornelia M Weyand, Johann Wojta.   

Abstract

PURPOSE OF REVIEW: Inflammation is a key component in cardiovascular disease. Controlling inflammatory events and their subsequent processes holds the potential for novel therapeutic treatment options. Cytokines are the propagators of inflammation. In this review we will discuss important cytokines including IL-6, TNF-α, MCP-1, fractalkine, M-CSF and GDF-15, and their effect on cardiac outcome. RECENT
FINDINGS: Recent studies have shed light on the role of IL-6 in cardiovascular disease. Long-term IL-6 levels are highly associated with coronary heart disease. Molecular studies indicate that a permanent prolongation of STAT signaling in cardiac myocytes might be a potential reason for the detrimental effects of IL-6. TNF-α was long considered to have detrimental effects on myocardial function but recent studies show cardioprotective mechanisms for TNF-α. Macrophage modulating cytokines emerge as interesting molecular targets to treat cardiovascular disease. Especially, the two different subtypes of monocytes, a pro-inflammatory and a reparative subset, and their different chemotactic properties might be possible drug targets. Finally, we discuss GDF-15, which emerges as a novel biomarker in cardiovascular disease reflecting information from several pathological pathways.
SUMMARY: Cytokines are the main proximal mediators of inflammation and hold the potential of being good molecular targets for novel treatment regimes. Cytokines might be valuable biomarkers, adding information about the pathologic pathways in cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21378564      PMCID: PMC4497511          DOI: 10.1097/QCO.0b013e328344f50f

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  52 in total

1.  Growth differentiation factor-15 and cardiovascular dysfunction and disease: malefactor or innocent bystander?

Authors:  Stefano Taddei; Agostino Virdis
Journal:  Eur Heart J       Date:  2010-03-18       Impact factor: 29.983

Review 2.  Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials.

Authors:  Laura Campbell; Chen Chen; Shweta S Bhagat; Richard A Parker; Andrew J K Östör
Journal:  Rheumatology (Oxford)       Date:  2010-11-14       Impact factor: 7.580

3.  The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury.

Authors:  Tibor Kempf; Matthias Eden; Jens Strelau; Marian Naguib; Christian Willenbockel; Jörn Tongers; Jörg Heineke; Daniel Kotlarz; Jian Xu; Jeffery D Molkentin; Hans W Niessen; Helmut Drexler; Kai C Wollert
Journal:  Circ Res       Date:  2006-01-05       Impact factor: 17.367

Review 4.  Chronic inflammation: importance of NOD2 and NALP3 in interleukin-1beta generation.

Authors:  L Ferrero-Miliani; O H Nielsen; P S Andersen; S E Girardin
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

5.  Reproducibility in serial C-reactive protein and interleukin-6 measurements in post-myocardial infarction patients: results from the AIRGENE study.

Authors:  Mahir Karakas; Jens Baumert; Sonja Greven; Regina Rückerl; Annette Peters; Wolfgang Koenig
Journal:  Clin Chem       Date:  2010-03-18       Impact factor: 8.327

6.  Continuous glycoprotein-130-mediated signal transducer and activator of transcription-3 activation promotes inflammation, left ventricular rupture, and adverse outcome in subacute myocardial infarction.

Authors:  Denise Hilfiker-Kleiner; Praphulla Shukla; Gunnar Klein; Arnd Schaefer; Britta Stapel; Melanie Hoch; Werner Müller; Michaela Scherr; Gregor Theilmeier; Matthias Ernst; Andres Hilfiker; Helmut Drexler
Journal:  Circulation       Date:  2010-06-28       Impact factor: 29.690

7.  The associations of interleukin-6 (IL-6) and downstream inflammatory markers with risk of cardiovascular disease: the Caerphilly Study.

Authors:  Christopher C Patterson; Anne E Smith; John W G Yarnell; Ann Rumley; Yoav Ben-Shlomo; Gordon D O Lowe
Journal:  Atherosclerosis       Date:  2009-09-27       Impact factor: 5.162

8.  Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

Authors:  Josef S Smolen; Andre Beaulieu; Andrea Rubbert-Roth; Cesar Ramos-Remus; Josef Rovensky; Emma Alecock; Thasia Woodworth; Rieke Alten
Journal:  Lancet       Date:  2008-03-22       Impact factor: 79.321

9.  Macrophage-modulating cytokines predict adverse outcome in heart failure.

Authors:  P J Hohensinner; K Rychli; G Zorn; M Hülsmann; R Berger; D Mörtl; B Richter; K Huber; J Wojta; R Pacher; A Niessner
Journal:  Thromb Haemost       Date:  2010-01-13       Impact factor: 5.249

10.  Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction.

Authors:  Sohail Q Khan; Kelvin Ng; Onkar Dhillon; Dominic Kelly; Paulene Quinn; Iain B Squire; Joan E Davies; Leong L Ng
Journal:  Eur Heart J       Date:  2009-01-23       Impact factor: 29.983

View more
  17 in total

1.  Acute myocardial infarction and cardiogenic shock: prognostic impact of cytokines: INF-γ, TNF-α, MIP-1β, G-CSF, and MCP-1β.

Authors:  R Prondzinsky; S Unverzagt; H Lemm; N Wegener; K Heinroth; U Buerke; M Fiedler; J Thiery; J Haerting; K Werdan; M Buerke
Journal:  Med Klin Intensivmed Notfmed       Date:  2012-07-20       Impact factor: 0.840

2.  The social environment and IL-6 in rats and humans.

Authors:  Katherine B Saxton; Neha John-Henderson; Matthew W Reid; Darlene D Francis
Journal:  Brain Behav Immun       Date:  2011-05-27       Impact factor: 7.217

3.  Treatment of patients with intermediate cardiovascular risk: Are clinical measures enough?

Authors:  Alfred A Bove; William P Santamore; Carol Homko; Abul Kashem; Robert Cross; Timothy R McConnell; Gail Shirk; Francis Menapace
Journal:  J Nucl Cardiol       Date:  2011-08-02       Impact factor: 5.952

4.  Regulatory Factor X1 Downregulation Contributes to Monocyte Chemoattractant Protein-1 Overexpression in CD14+ Monocytes via Epigenetic Mechanisms in Coronary Heart Disease.

Authors:  Sujie Jia; Shuang Yang; Pei Du; Keqin Gao; Yu Cao; Baige Yao; Ren Guo; Ming Zhao
Journal:  Front Genet       Date:  2019-11-01       Impact factor: 4.599

Review 5.  Inflammation, endoplasmic reticulum stress, autophagy, and the monocyte chemoattractant protein-1/CCR2 pathway.

Authors:  Pappachan E Kolattukudy; Jianli Niu
Journal:  Circ Res       Date:  2012-01-06       Impact factor: 17.367

6.  The Cardiomyocyte as a Source of Cytokines in Cardiac Injury.

Authors:  Toshinori Aoyagi; Takashi Matsui
Journal:  J Cell Sci Ther       Date:  2011-12-01

7.  Interleukin-1β reduces L-type Ca2+ current through protein kinase Cϵ activation in mouse heart.

Authors:  Nabil El Khoury; Sophie Mathieu; Céline Fiset
Journal:  J Biol Chem       Date:  2014-06-16       Impact factor: 5.157

Review 8.  Anxiety Disorders and Cardiovascular Disease.

Authors:  Christopher M Celano; Daniel J Daunis; Hermioni N Lokko; Kirsti A Campbell; Jeff C Huffman
Journal:  Curr Psychiatry Rep       Date:  2016-11       Impact factor: 5.285

Review 9.  Mechanisms and consequences of inflammatory signaling in the myocardium.

Authors:  Jihyun Ahn; Jaetaek Kim
Journal:  Curr Hypertens Rep       Date:  2012-12       Impact factor: 5.369

Review 10.  Mechanisms of load dependency of myocardial ischemia reperfusion injury.

Authors:  Mahmood S Mozaffari; Jun Yao Liu; Worku Abebe; Babak Baban
Journal:  Am J Cardiovasc Dis       Date:  2013-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.